NEW YORK, December 14, 2017 /PRNewswire/ --
In keeping with the commitment to dynamically provide members with timelyinformation, WallStEquities.com has issued free tailored Stock Review on AMGN, ALXN, ANAB, and AKCA which is a click away at http://www.wallstequities.com/registration. For today, WallStEquities.com covers these four equities in the Biotech space:
On Wednesday, shares in Thousand Oaks, California headquartered Amgen Inc. recorded a trading volume of 3.07 million shares, which was above their three months average volume of 2.74 million shares. The stock ended at $177.38, rising 0.64% from the last trading session. The Company's shares have gained 3.43% in the last one month and 21.32% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 0.24% and 3.05%, respectively. Furthermore, shares of Amgen, which discovers, develops, manufactures, and delivers human therapeutics worldwide, have a Relative Strength Index (RSI) of 56.30.
On December 11th, 2017, Amgen announced that the Amgen Foundation has pledged $500,000 to support victims of the Southern California wildfires. Of this commitment, $200,000 will be directed to the United Way of Ventura County to support their immediate relief efforts. The Foundation has also committed up to an additional $300,000 to support victims of the Southern California wildfires. Follow the link below to your free research report on AMGN at:
New Haven, Connecticut headquartered Alexion Pharmaceuticals Inc.'s stock finished yesterday's session 0.05% lower at $113.54 with a total trading volume of 1.87 million shares. The Company's shares have gained 0.08% in the last one month. The stock is trading below its 50-day moving average by 7.28%. Furthermore, shares of Alexion Pharma have an RSI of 47.88.
On December 07th, 2017, Alexion Pharma (ALXN) and Halozyme Therapeutics, Inc. (HALO) announced a collaboration and license agreement that enables the former to use HALO's ENHANZE® drug-delivery technology in the development of subcutaneous formulations for their portfolio of products. The agreement provides ALXN with the opportunity for exclusive development of up to four targets, including a next generation subcutaneous formulation of ALXN1210 (ALXN1210 SC), the Company's investigational long-acting C5 complement inhibitor, to potentially further extend the dosing interval of ALXN1210 SC to once every two weeks or once per month. The free technical report on ALXN can be accessed at:
At the close of trading on Wednesday, shares in San Diego, California-based AnaptysBio Inc. climbed 1.04%, ending the day at $88.02. The stock recorded a trading volume of 373,173 shares. The Company's shares have surged 23.57% in the last one month, 179.87% in the previous three months, and 417.76% since the start of this year. The stock is trading 27.07% and 138.73% above its 50-day and 200-day moving averages, respectively. Moreover, shares of AnaptysBio, which engages in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology in the US, have an RSI of 67.74.
On November 15th, 2017, research firm SunTrust initiated a 'Buy' rating on the Company's stock, with a target price of $115 per share. Sign up for free on Wall St. Equities and claim the latest report on ANAB at:
Cambridge, Massachusetts headquartered Akcea Therapeutics Inc.'s shares ended the day 3.95% higher at $19.20. A total volume of 462,667 shares was traded, which was above their three months average volume of 373,410 shares. The stock has gained 9.22% in the last month and 102.53% on an YTD basis. The Company's shares are trading 0.41% above their 200-day moving average. Additionally, shares of Akcea Therapeutics, which focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the US and internationally, have an RSI of 53.34.
On December 07th, 2017, Akcea Therapeutics announced that its management will present a Company overview at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference on December 14th, 2017, at 10:30 a.m. ET in New York. A live webcast of the presentation will be available under the "Media & Investors" section of the Company's website. See the free research coverage on AKCA at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: +21-32-044-483 Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Cushing syndrome is a collection of symptoms caused due to excessive amount of cortisol in the body ...
CAR T-cell therapy is a type of gene therapy where the patient's T-lymphocytes are genetically ...
Intermittent fasting is a complete or partial abstinence from food and caloric drinks for a ...View All